Mechanisms of neuropathic pain: The role of cytokines

Drug Discovery Today: Disease Mechanisms

Volumn 1, Issue 4, 2004, Pages 441-448

  Sommer, Claudia ^a   Schäfers, Maria ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADALIMUMAB; CYTOKINE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLODYNIA; APLASTIC ANEMIA; BACKACHE; CYTOKINE RELEASE; DEMYELINATING DISEASE; DRUG EFFECT; DRUG ERUPTION; DRUG MECHANISM; HUMAN; HYPERALGESIA; IMMUNOREACTIVITY; INJECTION SITE REACTION; NERVE CELL; NERVE EXCITABILITY; NERVE INJURY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PLEIOTROPY; RADICULOPATHY; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS;

EID: 23744447366     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2004.11.018     Document Type: Review

References (61)

1. Stefano, G.B. et al. (1998) Enkelytin and opioid peptide association in invertebrates and vertebrates: immune activation and pain. Immunol. Today 19, 265-268
2. Sommer, C. (2001) Cytokines and neuropathic pain. In Neuropathic Pain: Pathophysiology and Treatment (Hansson, P., Fields, H., Hill, R., Marchettini, P., eds), pp. 37-62, IASP press
3. Stoll, G. and Muller, H.W. (1999) Nerve injury, axonal degeneration and neural regeneration: basic insights. Brain Pathol. 9, 313-325
4. Wagner, R. and Myers, R.R. (1996) Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience 73, 625-629
5. Okamoto, K. et al. (2001) Pro- and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp. Neurol. 169, 386-391
6. Kleinschnitz, C. et al. (2004) The extent of cytokine induction in peripheral nerve lesions depends on the mode of injury and NMDA receptor signaling. J. Neuroimmunol. 149, 77-83
7. George, A. et al. (2004) Wallerian degeneration after crush or chronic constriction injury of rodent sciatic nerve is associated with a depletion of endoneurial interleukin-10 protein. Exp. Neurol. 188, 187-191
8. Murphy, P.G. et al. (1995)Induction of interleukin-6 in axotomized sensory neurons. J. Neurosci. 15, 5130-5138
9. Schäfers, M. et al. (2003) Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur. J. Neurosci. 17, 791-804
10. DeLeo, J.A. et al. (1997) Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res. 759, 50-57
11. Arruda, J.L. et al. (1998) Increase of interleukin-6 mRNA in the spinal cord following peripheral nerve injury in the rat: potential role of IL-6 in neuropathic pain. Brain Res. Mol. Brain Res. 62, 228-235
12. Winkelstein, B.A. et al. (2001) Nerve injury proximal or distal to the DRG induces similar spinal glial activation and selective cytokine expression but differential behavioral responses to pharmacologic treatment. J. Comp. Neurol 439, 127-139
13. Ignatowski, T.A. et al. (1999) Brain-derived TNFalpha mediates neuropathic pain. Brain Res. 841, 70-77
14. Covey, W.C. et al. (2000) Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. Brain Res. 859, 113-122
15. Watkins, L.R. et al. (2003) Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv. Exp. Med. Biol. 521, 1-21
16. Wagner, R. and Myers, R.R. (1996) Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport 7, 2897-2901
17. Sorkin, L.S. et al. (1997) Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 81, 255-262
18. Wagner, R. et al. (1998) Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-alpha expression. Pain 74, 35-42
19. Poole, S. et al. (1999) Hyperalgesia from subcutaneous cytokines. In Cytokines and Pain (Watkins, L.R. and Maier, S.F., eds), pp. 59-87, Birkhäuser
20. Glorioso, J.C. and Fink, D.J. (2004) Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu. Rev. Microbiol. 58, 253-271
21. Yao, M.Z. et al. (2002) Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience 112, 409-416
22. Sweitzer, S. et al. (2001) Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 103, 529-539
23. Flatters, S.J. et al. (2003) Spinal interleukin-6 (IL-6) inhibits nociceptive transmission following neuropathy. Brain Res. 984, 54-62
24. Milligan, E.D. et al. (2003) Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J. Neurosci. 23, 1026-1040
25. Onda, A. et al. (2003) Effects of neutralizing antibodies to tumor necrosis factor-alpha on nucleus pulposus-induced abnormal nociresponses in rat dorsal horn neurons. Spine 28, 967-972
26. Fukuoka, H. et al. (1994) Cutaneous hyperalgesia induced by peripheral injection of interleukin-1β in the rat. Brain Res. 657, 133-140
27. Opree, A. and Kress, M. (2000) Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1beta, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J. Neurosci. 20, 6289-6293
28. Obreja, O. et al. (2002) IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C. FASEB J. 16, 1497-1503
29. Junger, H. and Sorkin, L.S. (2000) Nociceptive and inflammatory effects of subcutaneous TNFalpha. Pain 85, 145-151
30. Diem, R. et al. (2001) Reduction of potassium currents and phosphatidylinositol 3-kinase-dependent AKT phosphorylation by tumor necrosis factor-(alpha) rescues axotomized retinal ganglion cells from retrograde cell death in vivo. J. Neurosci. 21, 2058-2066
31. Zhang, J.M. et al. (2002) Acute topical application of tumor necrosis factor alpha evokes protein kinase A-dependent responses in rat sensory neurons. J. Neurophysiol. 88, 1387-1392
32. Schäfers, M. et al. (2003) Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. J. Neurosci. 23, 3028-3038
33. Pollock, J. et al. (2002) TNF-alpha receptors simultaneously activate Ca2+ mobilisation and stress kinases in cultured sensory neurones. Neuropharmacology 42, 93-106
34. Schäfers, M. et al. (2003) Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J. Neurosci. 23, 2517-2521
35. Lindholm, D. et al. (1987) Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. Nature 330, 658-659
36. Safieh-Garabedian, B. et al. (1995) Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br. J. Pharmacol. 115, 1265-1275
37. Nicol, G.D. et al. (1997) Tumor necrosis factor enhances the capsaicin sensitivity of rat sensory neurons. J. Neurosci. 17, 975-982
38. Inoue, A. et al. (1999) Interleukin-1beta induces substance P release from primary afferent neurons through the cyclooxygenase-2 system. J. Neurochem. 73, 2206-2213
39. Thompson, S.W. et al. (1998) gp130 cytokines, leukemia inhibitory factor and interleukin-6, induce neuropeptide expression in intact adult rat sensory neurons in vivo: time-course, specificity and comparison with sciatic nerve axotomy. Neuroscience 84, 1247-1255
40. Raghavendra, V. et al. (2002) The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J. Neurosci. 22, 9980-9989
41. Sarno, E.N. et al. (1991) Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin. Exp. Immunol. 84, 103-108
42. Barnes, P.F. et al. (1992) Tumor necrosis factor production in patients with leprosy. Infect. Immun. 60, 1441-1446
43. Empl, M. et al. (2001) TNF-alpha expression in painful and nonpainful neuropathies. Neurology 56, 1371-1377
44. Lindenlaub, T. and Sommer, C. (2003) Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol. 105, 593-602
45. Kotani, N. et al. (2004) Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia. Am. J. Med. 116, 318-324
46. Brisby, H. et al. (2002) Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica. Eur. Spine J. 11, 62-66
47. Burke, J.G. et al. (2002) Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators. J. Bone Joint Surg. Br. 84, 196-201
48. Ahn, S.H. et al. (2002) mRNA expression of cytokines and chemokines in herniated lumbar intervertebral discs. Spine 27, 911-917
49. Tobinick, E.L. and Britschgi-Davoodifar, S. (2003) Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med. Wkly. 133, 170-177
50. Van Doorn, P.A. and Ruts, L. (2004) Treatment of chronic inflammatory demyelinating polyneuropathy. Curr. Opin. Neurol. 17, 607-613
51. Ching, D.W.T. et al. (2003) Successful treatment with low-dose thalidomide in a patinet with both Behcet's disease in complex regional pain syndrome type I. J. Clin. Rheumatol. 9, 96-98
52. Sommer, C. (1999) Thalidomide as a blocker of TNF production. Drugs Future 24, 67-75
53. Gorman, J.D. et al. (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N. Engl. J. Med. 346, 1349-1356
54. Karppinen, J. et al. (2003) Tumor necrosis factor-alpha monoclonal anti-body, infliximab, used to manage severe sciatica. Spine 28, 750-753 (discussion 753-754)
55. Moreland, L.W. et al. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141-147
56. Maini, R. et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 1932-1939
57. Lipsky, P.E. et al. (2000) nfliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in Rheumatoid ATTRACT Study Group. N. Engl. J. Med. 22, 1594-1602
58. Weinblatt, M.E. et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48, 35-45
59. Genevay, S. et al. (2004) Efficacy of etanercept in the treatment of acute and severe sciatica. A pilot study. Ann. Rheum. Dis. 63, 1120-1123
60. Fleischmann, R. et al. (2004) Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 4, 1333-1344
61. Mata, M. et al. (2004) Gene therapy: novel treatments for poly neuropathy and chronic pain. Curr. Neurol. Neurosci. Rep. 4, 1-2